新規登録 | ログイン | FAQ      [?] 
Recent | Unread | Search | Authors | Tags | Export

pjasper iressa [44 articles]

最近 pjasper さんのライブラリに追加された論文の中から タグ iressa. You can also see everyone's iressa.
  • ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Proc Natl Acad Sci U S A, Vol. 102, No. 10. (8 March 2005), pp. 3788-3793.
    by JA Engelman, PA Jänne, C Mermel, J Pearlberg, T Mukohara, C Fleet, K Cichowski, BE Johnson, LC Cantley
    posted to akt erbb3 inhibitor iressa nsclc by pjasper on 2007-05-22 18:40:08 as **
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    PLoS Med, Vol. 2, No. 3. (March 2005)
    by W Pao, VA Miller, KA Politi, GJ Riely, R Somwar, MF Zakowski, MG Kris, H Varmus
    posted to egfr iressa mutant resistance t790m tarceva by pjasper on 2007-05-10 20:41:10 as *****
  • Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Cancer Res, Vol. 61, No. 24. (15 December 2001), pp. 8887-8895.
    by SL Moulder, FM Yakes, SK Muthuswamy, R Bianco, JF Simpson, CL Arteaga
    posted to egfr erbb2 inactive_dimer iressa by pjasper on 2007-05-10 20:38:57 as *****
  • ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Clin Cancer Res, Vol. 9, No. 4. (April 2003), pp. 1274-1283.
    by J Anido, P Matar, J Albanell, M Guzmán, F Rojo, J Arribas, S Averbuch, J Baselga
    posted to egfr erbb2 erbb3 inactive_dimer iressa by pjasper on 2007-05-10 20:36:31 as ***** along with 1 person brianb
  • HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Cancer Res, Vol. 65, No. 10. (15 May 2005), pp. 4253-4260.
    by A Hirata, F Hosoi, M Miyagawa, S Ueda, S Naito, T Fujii, M Kuwano, M Ono
    posted to egfr erbb2 inhibitor iressa nsclc by pjasper on 2007-05-10 19:52:18 as ***** along with 1 person js229
  • Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Exp Cell Res, Vol. 313, No. 7. (15 April 2007), pp. 1361-1372.
    by X Liu, DL Carlisle, MC Swick, A Gaither-Davis, JR Grandis, JM Siegfried
    posted to egfr gastrin iressa resistance by pjasper on 2007-05-08 18:59:54 as **
  • The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Histochem Cell Biol, Vol. 127, No. 5. (May 2007), pp. 541-553.
    by Y Nishimura, B Bereczky, M Ono
    posted to egfr internalization iressa by pjasper on 2007-05-08 18:56:46 as **
  • Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
    Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2325-2330.
    by R Mulloy, A Ferrand, Y Kim, R Sordella, DW Bell, DA Haber, KS Anderson, J Settleman
    posted to egfr iressa mutation nsclc by pjasper on 2007-05-08 18:52:47 as **
  • Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Ann Oncol, Vol. 18, No. 4. (April 2007), pp. 752-760.
    by F Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, A Xavier, R Dziadziuszko, P Gumerlock, K Chansky, H West, A Gazdar, L Crino, D Gandara, W Franklin, P Bunn
    posted to amplification egfr inhibitor iressa nsclc by pjasper on 2007-05-08 18:46:53 as **
  • Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
    Clin Cancer Res, Vol. 12, No. 24. (15 December 2006), pp. 7242-7251.
    by M Ono, M Kuwano
    posted to egfr inhibitor iressa review by pjasper on 2007-04-26 17:44:12 as **
  • Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Clin Cancer Res, Vol. 12, No. 23. (1 December 2006), pp. 7117-7125.
    by BA Helfrich, D Raben, M Varella-Garcia, D Gustafson, DC Chan, L Bemis, C Coldren, A Barón, C Zeng, WA Franklin, FR Hirsch, A Gazdar, J Minna, PA Bunn
    posted to akt egfr genomics iressa mutation nsclc by pjasper on 2007-04-26 17:27:15 as **
  • Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
    Cancer Res, Vol. 66, No. 15. (1 August 2006), pp. 7708-7715.
    by MP Cunningham, H Thomas, Z Fan, H Modjtahedi
    posted to colon icr62 inhibitor iressa novel by pjasper on 2007-04-25 21:48:28 as **
  • Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Clin Cancer Res, Vol. 12, No. 13. (1 July 2006), pp. 3908-3914.
    by DM Jackman, BY Yeap, LV Sequist, N Lindeman, AJ Holmes, VA Joshi, DW Bell, MS Huberman, B Halmos, MS Rabin, DA Haber, TJ Lynch, M Meyerson, BE Johnson, PA Jänne
    posted to deletion iressa mutation nsclc by pjasper on 2007-04-25 21:23:34 as **
  • Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Clin Cancer Res, Vol. 12, No. 13. (1 July 2006), pp. 4103-4111.
    by K Erjala, M Sundvall, TT Junttila, N Zhang, M Savisalo, P Mali, J Kulmala, J Pulkkinen, R Grenman, K Elenius
    posted to erbb2 erbb3 inhibitor iressa resistance by pjasper on 2007-04-25 21:06:38 as **
  • EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer
    Oncogene, Vol. aop, No. current.
    by SH Choi, JM Mendrola, MA Lemmon,
    posted to activation egf-independent iressa mutation nsclc by pjasper on 2007-04-25 20:36:12 as **
  • Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    J Biol Chem, Vol. 281, No. 52. (29 December 2006), pp. 40183-40192.
    by M Perez-Torres, M Guix, A Gonzalez, CL Arteaga
    posted to iressa mutation resistance by pjasper on 2007-04-25 20:26:15 as **
  • Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
    British Journal of Cancer, Vol. aop, No. current. (07 November 2006)
    by H Yokoyama, Y Ikehara, Y Kodera, S Ikehara, Y Yatabe, Y Mochizuki, M Koike, M Fujiwara, A Nakao, M Tatematsu, H Nakanishi
    posted to erbb2 iressa resistance by pjasper on 2007-04-25 20:22:54 as ** along with 1 person klu
  • Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
    Genes Dev, Vol. 20, No. 11. (1 June 2006), pp. 1496-1510.
    by K Politi, MF Zakowski, PD Fan, EA Schonfeld, W Pao, HE Varmus
    posted to iressa mouse mutation nsclc by pjasper on 2007-04-25 20:09:14 as *****
  • PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.
    Cancer Res, Vol. 66, No. 10. (15 May 2006), pp. 5346-5353.
    by S Ueda, Y Basaki, M Yoshie, K Ogawa, S Sakisaka, M Kuwano, M Ono
    posted to akt iressa pten by pjasper on 2007-04-25 20:07:17 as **
  • Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Int J Cancer, Vol. 119, No. 11. (1 December 2006), pp. 2557-2566.
    by C Desbois-Mouthon, W Cacheux, MJ Blivet-Van Eggelpoël, V Barbu, L Fartoux, R Poupon, C Housset, O Rosmorduc
    posted to crosstalk igf iressa by pjasper on 2007-04-25 19:49:31 as **
  • AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
    Breast Cancer Res Treat, Vol. 102, No. 3. (May 2007), pp. 275-282.
    by MR Maiello, A D'Alessio, A De Luca, A Carotenuto, AM Rachiglio, M Napolitano, L Cito, A Guzzo, N Normanno
    posted to azd3409 breast iressa resistance by pjasper on 2007-04-25 19:45:44 as **
  • Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Cancer Res, Vol. 66, No. 7. (1 April 2006), pp. 3802-3812.
    by MS Pino, M Shrader, CH Baker, F Cognetti, HQ Xiong, JL Abbruzzese, DJ McConkey
    posted to activation iressa pancreas tgfa by pjasper on 2007-04-25 19:33:03 as **
  • Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.
    J Gastroenterol, Vol. 41, No. 2. (February 2006), pp. 166-176.
    by J Okano, K Matsumoto, T Nagahara, Y Murawaki
    posted to inhibitor iressa signaling by pjasper on 2007-04-25 19:26:09 as **
  • In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.
    Biochem J, Vol. 397, No. 3. (1 August 2006), pp. 537-543.
    by K Sakai, H Yokote, K Murakami-Murofushi, T Tamura, N Saijo, K Nishio
    posted to deletion iressa mutant by pjasper on 2007-04-25 16:46:50 as **
  • Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
    Cancer Res, Vol. 66, No. 2. (15 January 2006), pp. 944-950.
    by SE Witta, RM Gemmill, FR Hirsch, CD Coldren, K Hedman, L Ravdel, B Helfrich, R Dziadziuszko, DC Chan, M Sugita, Z Chan, A Baron, W Franklin, HA Drabkin, L Girard, AF Gazdar, JD Minna, PA Bunn
    posted to e-cadhering iressa nsclc by pjasper on 2007-04-25 16:19:49 as ** along with 1 person MllePapillon
  • The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    J Cell Physiol, Vol. 207, No. 2. (May 2006), pp. 420-427.
    by N Normanno, A De Luca, MR Maiello, M Campiglio, M Napolitano, M Mancino, A Carotenuto, G Viglietto, S Menard
    posted to iressa mapk resistance by pjasper on 2007-04-25 16:07:37 as **
  • High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
    Cancer Res, Vol. 65, No. 24. (15 December 2005), pp. 11478-11485.
    by N Fujimoto, M Wislez, J Zhang, K Iwanaga, J Dackor, AE Hanna, S Kalyankrishna, DD Cody, RE Price, M Sato, JW Shay, JD Minna, M Peyton, X Tang, E Massarelli, R Herbst, DW Threadgill, II Wistuba, JM Kurie
    posted to erbb2 erbb3 iressa ligands by pjasper on 2007-04-19 19:42:05 as **
  • Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Clin Cancer Res, Vol. 11, No. 24 Pt 1. (15 December 2005), pp. 8872-8879.
    by K Ando, T Ohmori, F Inoue, T Kadofuku, T Hosaka, H Ishida, T Shirai, K Okuda, T Hirose, N Horichi, K Nishio, N Saijo, M Adachi, T Kuroki
    posted to iressa nsclc tnf by pjasper on 2007-04-19 19:40:33 as **
  • EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
    Lung Cancer, Vol. 51, No. 3. (March 2006), pp. 363-368.
    by N Yoshimura, S Kudoh, T Kimura, S Mitsuoka, K Matsuura, K Hirata, K Matsui, S Negoro, K Nakagawa, M Fukuoka
    posted to ekb569 inhibitor iressa nsclc by pjasper on 2007-04-19 19:23:32 as **
  • HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
    British Journal of Cancer, Vol. aop, No. current. (15 November 2005)
    by F Cappuzzo, L Toschi, I Domenichini, S Bartolini, GL Ceresoli, E Rossi, V Ludovini, A Cancellieri, E Magrini, L Bemis, WA Franklin, L Crino, PA Bunn, FR Hirsch, M Varella-Garcia
    posted to amplification erbb3 iressa nsclc by pjasper on 2007-04-19 19:14:37 as **
  • Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Cancer Lett, Vol. 230, No. 1. (8 December 2005), pp. 33-46.
    by H Nakamura, S Takamori, T Fujii, M Ono, H Yamana, M Kuwano, K Shirouzu
    posted to herceptin inhibitor iressa nsclc by pjasper on 2007-04-19 19:02:16 as **
  • Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Nature Genetics, Vol. 37, No. 12. (30 October 2005), pp. 1315-1316.
    by Daphne W Bell, Ira Gore, Ross A Okimoto, Nadia Godin-Heymann, Raffaella Sordella, Roseann Mulloy, Sreenath V Sharma, Brian W Brannigan, Gayatry Mohapatra, Jeff Settleman, Daniel A Haber
    posted to iressa mutation nsclc t790m by pjasper on 2007-04-19 19:00:48 as **
  • Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L.
    Cancer Res, Vol. 65, No. 18. (15 September 2005), pp. 8151-8157.
    by PJ Real, A Benito, J Cuevas, MT Berciano, A de Juan, P Coffer, J Gomez-Roman, M Lafarga, JM Lopez-Vega, JL Fernandez-Luna
    posted to bnip3l breast iressa by pjasper on 2007-04-18 21:20:24 as **
  • Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
    PLoS Med, Vol. 2, No. 9. (September 2005)
    by CH Gow, JY Shih, YL Chang, CJ Yu
    posted to iressa l858r mutation by pjasper on 2007-04-18 21:16:11 as **
  • Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    J Clin Oncol, Vol. 23, No. 31. (1 November 2005), pp. 8081-8092.
    by DW Bell, TJ Lynch, SM Haserlat, PL Harris, RA Okimoto, BW Brannigan, DC Sgroi, B Muir, MJ Riemenschneider, RB Iacona, AD Krebs, DH Johnson, G Giaccone, RS Herbst, C Manegold, M Fukuoka, MG Kris, J Baselga, JS Ochs, DA Haber
    posted to amplification iressa mutation nsclc by pjasper on 2007-04-18 21:08:24 as **
  • Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
    Oncogene, Vol. aop, No. current.
    by YR Chen, YN Fu, CH Lin, ST Yang, SF Hu, YT Chen, SF Tsai, SF Huang,
    posted to activation iressa mutant by pjasper on 2007-04-18 21:07:17 as **
  • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
    PLoS Med, Vol. 2, No. 11. (November 2005)
    by H Greulich, TH Chen, W Feng, PA Jänne, JV Alvarez, M Zappaterra, SE Bulmer, DA Frank, WC Hahn, WR Sellers, M Meyerson
    posted to iressa mutant transformation by pjasper on 2007-04-18 20:56:06 as ***
  • Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
    British Journal of Cancer, Vol. aop, No. current. (27 September 2005)
    by MW Pedersen, N Pedersen, LH Ottesen, HS Poulsen
    posted to iressa v3 by pjasper on 2007-04-18 20:54:47 as **
  • Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    J Natl Cancer Inst, Vol. 97, No. 16. (17 August 2005), pp. 1185-1194.
    by T Mukohara, JA Engelman, NH Hanna, BY Yeap, S Kobayashi, N Lindeman, B Halmos, J Pearlberg, Z Tsuchihashi, LC Cantley, DG Tenen, BE Johnson, PA Jänne
    posted to c225 iressa nsclc by pjasper on 2007-04-18 20:44:20 as read
  • Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    J Clin Oncol, Vol. 23, No. 22. (1 August 2005), pp. 5007-5018.
    by F Cappuzzo, M Varella-Garcia, H Shigematsu, I Domenichini, S Bartolini, GL Ceresoli, E Rossi, V Ludovini, V Gregorc, L Toschi, WA Franklin, L Crino, AF Gazdar, PA Bunn, FR Hirsch
    posted to amplification erbb2 iressa nsclc by pjasper on 2007-04-18 20:38:35 as ***
  • Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Cancer Res, Vol. 65, No. 15. (1 August 2005), pp. 6943-6949.
    by CH Yang, CJ Huang, CS Yang, YC Chu, AL Cheng, J Whang-Peng, PC Yang
    posted to atp iressa by pjasper on 2007-04-18 20:34:32 as ***
  • Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
    Proc Natl Acad Sci U S A, Vol. 102, No. 31. (2 August 2005), pp. 11011-11016.
    by TA Carter, LM Wodicka, NP Shah, AM Velasco, MA Fabian, DK Treiber, ZV Milanov, CE Atteridge, WH Biggs, PT Edeen, M Floyd, JM Ford, RM Grotzfeld, S Herrgard, DE Insko, SA Mehta, HK Patel, W Pao, CL Sawyers, H Varmus, PP Zarrinkar, DJ Lockhart
    posted to iressa mutant by pjasper on 2007-04-18 20:30:01 as *** along with 1 person preeves
  • Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    J Clin Oncol, Vol. 23, No. 28. (1 October 2005), pp. 6829-6837.
    by T Takano, Y Ohe, H Sakamoto, K Tsuta, Y Matsuno, U Tateishi, S Yamamoto, H Nokihara, N Yamamoto, I Sekine, H Kunitoh, T Shibata, T Sakiyama, T Yoshida, T Tamura
    posted to iressa mutation nsclc by pjasper on 2007-04-18 19:31:19 as ***
  • notes Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.
    Breast Cancer Res, Vol. 7, No. 4. (2005)
    by A Camirand, M Zakikhani, F Young, M Pollak
    posted to apoptosis breast igf iressa by pjasper on 2007-04-18 18:37:59 as **
    • 注: このページを引用する時は次のURLでどうぞ: http://www.citeulike.org/user/pjasper/tag/iressa

    RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.